NDA 021351 · Allergan
Oxytrol
Oxybutynin · Transdermal · Cholinergic Muscarinic Antagonist
Last checked: Nov 20, 2026Latest source record: May 29, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2003
Feb 26, 2003
Approved uses
1
Original approval plus efficacy supplements
Registered trials
103
25 Phase 3, 9 recruiting
FAERS reports
23,120
13,881 serious, 1,707 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect May 29, 2024.
OXYTROL is a muscarinic antagonist indicated for the treatment of overactive bladder in men with symptoms of urge urinary incontinence, urgency, and frequency. OXYTROL is a muscarinic antagonist indicated for the treatment of overactive bladder in men with symptoms of urge urinary incontinence, urgency, and frequency. ( 1 )
Mechanism: The free base form of oxybutynin is pharmacologically equivalent to oxybutynin hydrochloride. Oxybutynin acts as a competitive antagonist of acetylcholine at postganglionic muscarinic receptors, resulting in relaxation of bladder smooth muscle. In patients with conditions characterized by involuntary detrusor contractions, cystometric studies have demonstrated that oxybutynin increases maximum urinary bladder capacity and increases the volume to first detrusor contraction. Oxybutynin is a racemic (50:50) mixture of R- and S-isomers. Antimuscarinic activity resides predominantly in the...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- OXYTROL · OXYBUTYNIN 3.9MG/24HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Oxybutynin" as an intervention, any sponsor and status, largest first.
- Transdermal (TDS) Oxybutynin (Oxytrol(r)) in Overactive BladderPivotal-lookingCompleted
Watson PharmaceuticalsIndustry
NCT00224146 · 2,878 participants · Start May 2004 · Primary completion May 2005
Drug: oxybutynin transdermal delivery system (Oxytrol(r)) · For: Overactive Bladder; Urinary Incontinence; Quality of Life
Sites: Mobile, Alabama; Tucson, Arizona; Torrance, California · 10 sites in all
- A Comparative Effectiveness Study of Positive Airway Pressure (PAP) Therapy, Dental Device, and Atomoxetine-Oxybutynin for Treatment of Obstructive Sleep Apnea in AdultsPivotal-lookingRecruiting
Sairam ParthasarathyAcademic, hospital or other
NCT07679282 · 2,400 participants (planned) · Start Sep 4, 2026 · Primary completion Mar 1, 2030
Drug: Atomoxetine-oxybutynin · For: Obstructive Sleep Apnea (OSA)
Sites: Tucson, Arizona; Redwood City, California; Miami, Florida · 4 sites in all
- Study to Gather Information About the Actual Use of an Adhesive Patch Placed on the Skin to Deliver Oxytrol Through the Skin Into the Bloodstream.Pivotal-lookingCompleted
BayerBayer (BAYRY)
NCT04534491 · 855 participants · Start May 25, 2010 · Primary completion Jun 22, 2011
Drug: Oxybutynin (Oxytrol, BAY839380) · For: Overactive Bladder
Sites: Saint Joseph, Missouri
- Efficacy and Tolerability of DITROPAN XL (Oxybutynin Chloride) Versus DETROL LA (Tolterodine Tartrate) in Treatment of Overactive BladderPivotal-lookingCompleted
Alza Corporation, DE, USAIndustry
NCT00293839 · 790 participants
Drug: oxybutynin chloride · For: Urinary Incontinence
- A Comparison of a New Drug to Treat Overactive Bladder vs. PlaceboPivotal-lookingCompleted
Watson PharmaceuticalsIndustry
NCT00350636 · 789 participants · Start Jun 2006 · Primary completion May 2007
Drug: Oxybutynin topical gel · For: Overactive Bladder
Sites: Birmingham, Alabama; Homewood, Alabama; Mobile, Alabama · 63 sites in all
- Study of Topically Administered Oxybutynin Gel in Patients With Urge IncontinencePivotal-lookingCompleted
Antares Pharma Inc.Industry
NCT00909181 · 626 participants · Start Mar 2009 · Primary completion Jul 2010
Drug: Oxybutynin; Placebo · For: Urge Urinary Incontinence; Urinary Frequency
Sites: Birmingham, Alabama; Little Rock, Arkansas; Laguna Hills, California · 55 sites in all
- InSite for Over Active BladderPivotal-lookingCompleted
MedtronicNeuroIndustry
NCT00547378 · 571 participants · Start Oct 2007 · Primary completion Aug 2016
Drug: Standard Medical Therapy · For: Urinary Incontinence, Urgency-frequency; Overactive Bladder
- Desloratadine With Oxybutynin for the Treatment of Seasonal Allergic Rhinitis and Post-Nasal Drip (Study P04258)(COMPLETED)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00816972 · 540 participants · Start Apr 2005 · Primary completion Jun 2005
Drug: Desloratadine 2.5 mg; Oxybutynin 2.5 mg and 2 more · For: Post-nasal Drip; Seasonal Allergic Rhinitis; Rhinorrhea
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective1,792
- fatigue1,543
- fall1,497
- nausea1,185
- diarrhoea1,075
- urinary tract infection1,053
- dizziness1,039
- pain1,012
- headache949
- off label use930
- asthenia903
- dyspnoea757
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 203 |
| 2005 | 250 |
| 2006 | 188 |
| 2007 | 73 |
| 2008 | 80 |
| 2009 | 123 |
| 2010 | 370 |
| 2011 | 595 |
| 2012 | 739 |
| 2013 | 746 |
| 2014 | 1,222 |
| 2015 | 1,549 |
| 2016 | 1,829 |
| 2017 | 1,897 |
| 2018 | 2,032 |
| 2019 | 2,072 |
| 2020 | 1,786 |
| 2021 | 1,489 |
| 2022 | 1,470 |
| 2023 | 1,370 |
| 2024 | 1,014 |
| 2025 | 1,179 |
| 2026 | 843 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Oxytrol (Oxybutynin)
2024 spending
$1.4M
Beneficiaries
425
1,434 claims
Per beneficiary
$3,248
$82.99 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $2,942,541 |
| 2021 | $2,587,140 |
| 2022 | $2,200,353 |
| 2023 | $1,799,809 |
| 2024 | $1,380,315 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Treatment of urge incontinence in postmenopausal women: A systematic review.
Bapir R, Bhatti KH, Eliwa A, et al. · Arch Ital Urol Androl 2023 · Meta-Analysis, Systematic Review
- Nocturnal enuresis.
Kiddoo D · BMJ Clin Evid 2011 · Systematic Review
- Nocturnal enuresis.
Kiddoo D · BMJ Clin Evid 2007 · Systematic Review
- Comparative assessment of efficacy and safety of approved oral therapies for overactive bladder: a systematic review and network meta-analysis.
He W, Huang G, Cui W, et al. · Int Braz J Urol 2023 · Systematic Review, Network Meta-Analysis
- Interventions for primary vesicoureteric reflux.
Williams G, Hodson EM, Craig JC · Cochrane Database Syst Rev 2019 · Meta-Analysis, Research Support, Non-U.S. Gov't
- The Combination of Atomoxetine and Oxybutynin Greatly Reduces Obstructive Sleep Apnea Severity. A Randomized, Placebo-controlled, Double-Blind Crossover Trial.
Taranto-Montemurro L, Messineo L, Sands SA, et al. · Am J Respir Crit Care Med 2019 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
Sponsor: AbbVie
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.